Showing 6131-6140 of 7509 results for "".
- FDA Grants Breakthrough Status for Baricitinib in AAhttps://practicaldermatology.com/news/fda-grants-breakthrough-status-for-baricitinib-in-alopecia-1/2460308/The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Eli Lilly and Company and Incyte Corporation’s baricitinib for the treatment of alopecia areata (AA). Baricitinib is currently approved for the treatment of adults with moderately to severe
- Special Report: An Overview of Coronavirus by Dr. Jonathan Kaplanhttps://practicaldermatology.com/news/special-report-an-overview-of-coronavirus-by-dr-jonathan-kaplan/2460306/Wash your hands, wipe down surfaces, don’t touch your face, and practice social distancing. If nothing else, that’s what you should take away from this coronavirus overview. But keep reading to learn important details about this epidemic. Such as, how we can make it end with less coll
- Viper Equity Partners Seeks to Expand into Florida and Georgia Dermatology Marketshttps://practicaldermatology.com/news/viper-equity-partners-seeks-to-expand-into-florida-and-georgia-dermatology-markets/2460303/Viper Equity Partners is turning its attention to key dermatology and related aesthetics offices in Florida and Georgia to join private equity-backed partnerships. In an effort spearheaded by Senior Vice President Nina Das (see photo), the North Palm Beach-based M&A advisory firm is
- Galderma Rolls Out New Consumer-Facing Rewards App, Plus Morehttps://practicaldermatology.com/news/galderma-rolls-out-new-consumer-facing-rewards-app-plus-more-1/2460296/Galderma is enhancing its aesthetic portfolio with digital enhancements to Aspire Galderma Rewards, an expansion of its U.S. salesforce plus a collaboration with ZO Skin Health. "We want to enable every customer and partner to build experiences on our leading platforms,&q
- Sciton Names New CEOhttps://practicaldermatology.com/news/sciton-names-new-ceo/2460292/Aaron Burton is Sciton Inc.’s new Chief Executive Officer. Aaron has spent the last eight years at Sciton growing the Aesthetic Sales Team, Women’s Health Group, International Sales Team and more recently operations in our World Head
- Dermatologists React to Threat of Coronavirus Pandemichttps://practicaldermatology.com/news/dermatologists-react-to-threat-of-coronavirus-pandemic/2460291/Reports about COVID-19 are causing many dermatologists to rethink their travel plans and update their office policy on the care of sick patients. The International Health Regulations Emergency Committee of the World Health Organization declared the outbreak a “public health emerge
- BTL Files Suit Against Allergan, Alleges Misleading Advertisinghttps://practicaldermatology.com/news/btl-files-suit-against-allergan-alleges-misleading-advertising/2460288/In a new lawsuit filed this week, BTL Industries alleges that Allergan launched a wide-ranging false and misleading advertising campaign relating to BTL's EMSCULPT device for non-invasive muscle toning and body shaping. The suit alleges that Allergan's marketing, sales materials, and soci
- Business News: Lilly, Dermira Acquisition Completehttps://practicaldermatology.com/news/business-news-lilly-dermira-acquisition-complete/2460287/Eli Lilly and Company has completed its acquisition of Dermira, Inc. The acquisition expands Lilly's immunology pipeline with the addition of lebrikizumab, a novel, investigational, monoclonal antibody designed to bind IL-13 that is being evaluated in a Phase 3 clinical development
- Foamix’s Rosacea Candidate Shows Promise in Phase 3 Studieshttps://practicaldermatology.com/news/foamixs-rosacea-candidate-shows-promise-in-phase-3-studies-1/2460286/Foamix Pharmaceuticals Ltd.’s FMX103 1.5% Topical Minocycline Foam for rosacea performed well in an integrated efficacy analysis of two pivotal Phase 3 clinical trials presented at the 17th Annual South Beach Symposium in Dermatology in Miami,
- Acne Pipeline Watch: Dermata Therapeutics Completes Enrollment in Phase 2b Trial of Once-Weekly Topical DMT310 for Acnehttps://practicaldermatology.com/news/acne-pipeline-watch-dermata-therapeutics-completes-enrollment-in-phase-2b-trial-of-once-weekly-topical-dmt310-for-acne/2460282/Dermata Therapeutics, LLC completed enrollment of patients in its Phase 2b clinical trial evaluating the safety, tolerability and efficacy of DMT310 in moderate to severe acne patients. The Phase 2b trial enrolled 182 patients randomly in two group